CMP Pharma, Inc. drugs

10 results

  • atorvaliq

    (ATORVALIQ)
    CMP Pharma, Inc.
    ATORVALIQ is indicated to reduce the risk of cardiovascular events in adults with risk factors for coronary heart disease, type 2 diabetes, and clinically evident coronary heart disease. It also lowers LDL cholesterol in various conditions, including primary hyperlipidemia and familial hypercholesterolemia, as an adjunct to diet or other therapies.
    Medication Details

  • carospir

    (CaroSpir)
    CMP Pharma, Inc.
    CAROSPIR is indicated for treating NYHA Class III-IV heart failure and reduced ejection fraction in adults to improve survival and reduce hospitalization. It also serves as an add-on therapy for hypertension management and is used for managing edema in cirrhotic patients unresponsive to fluid or sodium restriction.
    Medication Details

  • norliqva

    (amlodipine)
    CMP Pharma, Inc.
    NORLIQVA® is indicated for treating hypertension in adults and children ages 6 and older, reducing cardiovascular event risk. It also treats chronic stable angina, vasospastic angina, and helps patients with angiographically documented coronary artery disease to lower hospitalization and revascularization risks. It can be used alone or with other agents.
    Medication Details
    Drug Interactions

  • potassium phosphates - monobasic potassium phosphate and dibasic potassium phosphate injection

    (Monobasic Potassium Phosphate And Dibasic Potassium Phosphate)
    Cmp Pharma, Inc.
    Medication Details

  • tadliq

    (Tadalafil)
    CMP Pharma, Inc.
    TADLIQ® is indicated for treating pulmonary arterial hypertension (PAH) in patients to improve exercise ability, particularly those with NYHA Functional Class II-III symptoms due to idiopathic or heritable PAH or PAH associated with connective tissue diseases.
    Medication Details
    Drug Interactions